May 6, 2020 / 12:06 PM / a month ago

BRIEF-AB Science Initiates Phase 2 Study Evaluating Masitinib In Combination With Isoquercetin For Treatment Of COVID-19

May 6 (Reuters) - AB Science SA:

* REG-AB SCIENCE GRANTED AUTHORIZATION BY ANSM TO INITIATE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN FOR THE TREATMENT OF COVID-19

* AB SCIENCE SA - STUDY WILL ENROLL 200 PATIENTS AT MEDICAL CENTERS IN FRANCE AND OTHER COUNTRIES

* AB SCIENCE SA - ANNOUNCES INITIATION OF A PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN FOR TREATMENT OF COVID-19, FOLLOWING RAPID REVIEW AND ACCEPTANCE RECEIVED FROM FRENCH MEDICINE AGENCY, ANSM.

* AB SCIENCE SA - PRIMARY OBJECTIVE IS TO IMPROVE CLINICAL STATUS OF PATIENTS AFTER 15 DAYS OF TREATMENT. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below